At each post-baseline visit, mean weight had decreased compared to baseline, but mean decreases were not greater than 0.23 kg below baseline at any time point.
However, in contrast to the BoNT-Ainjected subjects, the VM VL ratio in placebo subjects was not significantly different from baseline at any time point (figure 4A).
Potential clinically significant increases in serum creatinine (serum creatinine ≥1.5 mg/dl and at least 50% greater than baseline at any time point through the EOT visit) were more common in telavancin-treated patients (5/25 vs. 2/28).
Potential clinically significant increases in serum creatinine (serum creatinine ≥1.5 mg/dL and at least 50% greater than baseline at any time point through the end-of-therapy visit) were more common in telavancin-treated patients (5/25 vs 2/28).
There was no evidence of a difference between the treatment groups in the change in FACT-B+ES score from baseline at any time point (mean change at 24 months: −2.72, 95% CI: −6.42, 0.99; P=0.15 and mean change at 60 months: −1.14, 95% CI: −7.54, 5.26; P=0.73).
Similar to TOI, there was no evidence of a difference between the treatment groups in the change in ES score from baseline at any time point (mean change at 24 months: 0.42, 95% CI: −0.91, 1.74; P=0.54 and mean change at 60 months: −0.25, 95% CI: −2.40, 1.89; P=0.82).
In the primary analysis, none of the placebo-corrected changes from baseline at any time point for either granisetron preparation exceeded 1.9 milliseconds (msec), and the maximum observed 90% upper confidence boundary was 6.88 msec, well below the threshold of 10 msec for regulatory concern.
Run immediately to the baseline at a point in between the lane line and the three-point line.
Moderately high altitude group had lower heart rate values at baseline, at any time points during surgery and postoperative 1st and 2nd hours compared to the sea level group (P < 0.05).
Our response criteria were purposely broad in that a decline from baseline in CA19-9 anyany point in time after initiation of treatment, whether early or late, was counted as a biomarker response, although a significant proportion of patients who responded did so within the first 2 months of therapy.
